Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-PSMA-617 versus switch to alternate ARDT in taxane-naive Chinese men with progressive PSMA-positive mCRPC
CTR20230581Phase 2Active
- Sponsor
- Advanced Accelerator Applications
- Start
- Jun 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Advanced Accelerator Applications. Started Jun 2023; status: active.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20230581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230581.